

Marta Valenciano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3380139/publications.pdf>

Version: 2024-02-01

22
papers

1,164
citations

471509

17
h-index

677142

22
g-index

26
all docs

26
docs citations

26
times ranked

1425
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009â€“2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study. PLoS Medicine, 2011, 8, e1000388.	8.4	137
2	Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine, 2013, 31, 5634-5642.	3.8	109
3	I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe. PLoS ONE, 2011, 6, e27622.	2.5	95
4	I-MOVE multicentre caseâ€“control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?. Eurosurveillance, 2016, 21, .	7.0	91
5	Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine, 2010, 28, 7381-7388.	3.8	90
6	Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Caseâ€“Control Study, Europe 2014/15. Eurosurveillance, 2016, 21, pii=30139.	7.0	66
7	Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. Eurosurveillance, 2018, 23, .	7.0	62
8	Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019. Eurosurveillance, 2019, 24, .	7.0	56
9	Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVIDâ€“19 pandemic. Influenza and Other Respiratory Viruses, 2022, 16, 7-13.	3.4	51
10	The European I-MOVE Multicentre 2013â€“2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2). Vaccine, 2015, 33, 2813-2822.	3.8	50
11	Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Eurosurveillance, 2020, 25, .	7.0	50
12	Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance networkâ€“Pilot caseâ€“control studies using different control groups, 2008â€“2009 season, Spain. Vaccine, 2010, 28, 2903-2907.	3.8	40
13	Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15â€“64-year-olds in Europe: exploration by birth cohort. Eurosurveillance, 2019, 24, .	7.0	35
14	2015/16 I-MOVE+ multicentre caseâ€“control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineageâ€“mismatched influenza B among children. Influenza and Other Respiratory Viruses, 2018, 12, 423-437.	3.4	29
15	2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. Eurosurveillance, 2017, 22, .	7.0	29
16	Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I-MOVE multicentre testâ€“negative caseâ€“control study, 2011/2012â€“2016/2017. Influenza and Other Respiratory Viruses, 2018, 12, 567-581.	3.4	23
17	Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016â€“17 and 2017â€“18). Vaccine: X, 2019, 3, 100042.	2.1	22
18	Absence of association between 2019â€“20 influenza vaccination and COVIDâ€“19: Results of the European I-MOVEâ€“COVIDâ€“19 primary care project, Marchâ€“August 2020. Influenza and Other Respiratory Viruses, 2021, 15, 429-438.	3.4	21

#	ARTICLE	IF	CITATIONS
19	Vaccine effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 302-310.	3.4	15
20	Estimating the effect of influenza vaccines. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 5-6.	9.1	9
21	Household transmission of SARS-CoV-2: a prospective observational study in Bosnia and Herzegovina, August-December 2020. <i>International Journal of Infectious Diseases</i> , 2021, 112, 352-361.	3.3	8
22	Transmission of SARS-CoV-2 in standardised first few X cases and household transmission investigations: A systematic review and meta-analysis. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 803-819.	3.4	6